The natural RNAi mechanism can be directed by either short interfering RNA (siRNA) or microRNA (miRNA). 1 There are four key steps in the RNAi pathway. When miRNA acts as the guide for RNAi, only a ...

The discovery of RNAi dates back to the 1990s when researchers observed unexpected gene silencing in plants and fungi. In 1998, Andrew Fire and Craig Mello published a groundbreaking study ...

RNA interference (RNAi) therapeutics have garnered significant attention in clinical research due to their potential for treating various diseases, including genetic disorders, viral infections and ...

D. Grimm et al., "Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways," Nature, 441:537-41, 2006. (Cited in 147 papers) While studying the potential of RNA ...

Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...

A new possibility for managing cardiovascular disease through RNA interference (RNAi) gene therapies. As cardiovascular diseases continue to be the leading cause of death globally, this technology ...

Endogenous RNA is central to protein control and, ultimately, cellular function. Synthetic RNA is an important tool for biological research and is also offering a new generation of promising ...

Enticed by the immense market opened by GLP-1 weight loss drugs Wegovy and Zepbound, a handful of biotech companies are trying to develop next-generation, longer-lasting therapies based on a very ...

Parkinson’s disease is associated with the buildup of a particular brain protein that currently has no approved therapies addressing it. Novartis was among the companies pursuing this target, but its ...

An RNA interference therapy, targeting ANGPTL3 in the liver, drastically reduced fasting triglycerides in people with mixed hyperlipidemia, the ARCHES-2 trial showed. Used atop usual statins and other ...